|Articles|July 1, 1999

July 1999
Volume 5
Issue 7

Hospital Expenditures and Utilization: The Impact of HMOs

Author(s)Gerard F. Anderson, PhD, Nannan Zhang, PhD, Chantal Worzala, MPA

Download PDF: Hospital Expenditures and Utilization: The Impact of HMOs

Articles in this issue

about 27 years ago

Article

The Cost of Alzheimer's Disease in Managed Care: A Cross-Sectional Study

about 27 years ago

Article

Efficacy and Cost Effectiveness of Lansoprazole Versus Omeprazole in Maintenance Treatment of Symptomatic Gastroesophageal Reflux Disease

about 27 years ago

Article

Payor Cost Savings with Endometrial Ablation Therapy

about 27 years ago

Article

The Food and Drug Administration and Atrial Defibrillation Devices

about 27 years ago

Article

Benign Prostatic Hyperplasia: New Concepts for the Millennium

about 27 years ago

Article

Breast Cancer Prevention: The Role of Antiestrogens

about 27 years ago

Article

The Impact of HMOs on Hospital Use and Cost? A Matter of Interpretation

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Hospital Expenditures and Utilization: The Impact of HMOs

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

Medicaid MFN Pricing Could Save $8.6 Billion

Cardiology Prices Vary Widely by Insurer and State

CRC Treatment Delays Linked to Higher Metastasis Risk, Supporting Pathway-Specific Benchmarks

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

Hepatitis Prevention Programs Improve Liver Outcomes, but Gaps in Screening, Care Remain